This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses.
Biomarkers in Alzheimer's Disease provides a comprehensive overview of all modalities of Alzheimer's disease biomarkers, including neuroimaging, cerebrospinal fluid, genomic, and peripheral systems. Each chapter integrates molecular/cellular abnormality due to Alzheimer's disease and technological advancement of biomarkers techniques. The book is ideal for clinical neuroscience and molecular/cellular neuroscience researchers, psychiatrists, and allied healthcare practitioners involved in the diagnosis and management of patients with cognitive impairment and Alzheimer's disease, and for differential diagnosis of Alzheimer's disease with other non-Alzheimer's dementia. - Presents a comprehensive overview detailing all modalities of Alzheimer's disease biomarkers - Written for neuroscience researchers and clinicians studying or treating patients with Alzheimer's Disease - Integrates, in each chapter, the molecular/cellular abnormality due to Alzheimer's disease and the technological advancement of biomarkers techniques
Cerebrospinal Fluid in Neurologic Disorders, Volume 146 provides a brief overview on the current use of CSF in clinical routine, the physiology of CSF, and its usefulness and potential as a biomarker. The second part addresses the main purpose of the volume, describing CSF from a research perspective in context with the most important diagnostic entities in neurology. The book's authors provide insight into the current understanding of CSF changes in these various conditions and what it tells us about the nature of neurological diseases. Furthermore, methodological aspects are discussed, as are shortcomings that need to be addressed. Finally, the book provides an outlook for potential directions that can be explored to improve the various aspects of CSF research with the ultimate goal of being incorporated in clinical practice. - Provides a brief overview on the current use of CSF in clinical routine, the physiology of CSF, and its usefulness and potential as a biomarker - Addresses relevant research in context with the most important diagnostic entities in neurology - Edited by leading authors in CSF research from around the globe, presenting the broadest, most expert coverage available
Due to injuries sustained in sports and in combat, interest in traumatic brain injury (TBI) has never been greater. This book will fulfill a gap in understanding of what is occurring in the brain following injury that can subsequently be detected in biological fluids and imaging.
This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer's disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses.
The cerebrospinal fluid (CSF) is an invaluable diagnostic tool in clinical neurology, not only in the evaluation of inflammatory, degenerative, and malignant diseases of the nervous system, but also in the diagnosis of all forms of cerebral and subarachnoidal bleedings. The CSF can be easily obtained by lumbar puncture and a set of basic analyses can be conducted using relatively simple laboratory methods. By combining different CSF parameters, a wide range of diagnostic entities can be identified. However, properly interpreting the test results requires a high level of expertise and cannot be achieved by just reporting on individual analytic values. This book covers essential aspects of cerebrospinal fluid analysis and its use in the diagnosis of common neurological diseases. The first part addresses preclinical aspects such as the history of CSF, as well as the anatomical, physiological, and biological background of this valuable fluid. In addition, CSF collection, its preanalytical and methodological implications, and the increasing number of disease-specific markers in CSF are discussed in detail. Lastly, CSF analyses are put into context with clinical syndromes, demonstrating their diagnostic value in neurological clinical practice. Cerebrospinal Fluid in Clinical Neurology helps readers understand the preanalytical and analytical aspects of CSF diagnostics and offers a valuable reference guide for interpreting CSF results during the clinical work-up for neurological patients.
Sex and Gender Differences in Alzheimer's Disease: The Women's Brain Project offers for the first time a critical overview of the evidence documenting sex and gender differences in Alzheimer's disease neurobiology, biomarkers, clinical presentation, treatment, clinical trials and their outcomes, and socioeconomic impact on both patients and caregivers. This knowledge is crucial for clinical development, digital health solutions, as well as social and psychological support to Alzheimer's disease families, in the frame of a precision medicine approach to Alzheimer's disease.This book brings together up-to-date findings from a variety of experts, covering basic neuroscience, epidemiology, diagnosis, treatment, clinical trials development, socioeconomic factors, and psychosocial support. Alzheimer's disease, the most common form of dementia, remains an unmet medical need for the planet. Wide interpersonal variability in disease onset, presentation, and biomarker profile make Alzheimer's a clinical challenge to neuroscientists, clinicians, and drug developers alike, resulting in huge management costs for health systems and society. Not only do women represent the majority of Alzheimer's disease patients, but they also represent two-thirds of caregivers. Understanding sex and gender differences in Alzheimer's disease will lead to novel insights into disease mechanisms, and will be crucial for personalized disease management strategies and solutions, involving both the patient and their family. Endorsements/Reviews: "There is a clear sex and gender gap in outcomes for brain health disorders like Alzheimer's disease, with strikingly negative outcomes for women. This understanding calls for a more systematic way of approaching this issue of inequality. This book effectively highlights and frames inequalities in all areas across the translational spectrum from bench-to-bedside and from boardroom-to-policy and economics. Closing the Brain Health Gap will help economies create recovery and prepare our systems for future global shocks." Harris A. Eyre MBBS, PhD, co-lead, Neuroscience-inspired Policy Initiative, OECD and PRODEO Institute. Instructor in Brain Health Diplomacy, Global Brain Health Institute, UCSF and TCD. "Sex and Gender Differences in Alzheimer's disease is the most important title to emerge on Alzheimer's disease in recent years.This comprehensive, multidisciplinary book is a must read for anyone with a serious interest in dementia prevention, diagnosis, treatment, care, cure and research. Precision medicine is the future of healthcare and this book represents an incredible and necessary resource to guide practice, policy and research in light of the fact that Alzheimer's disease disproportionately affects women. The combination of contributions from the most eminent experts and the most up-to-date research makes this an invaluable resource for clinicians, care providers, academics, researchers and policy makers. Given the complex nature of dementia and the multiple factors that influence risk and disease trajectory the scope of the book is both impressive and important covering sex differences in neurobiological processes, sex and gender differences in clinical aspects and gender differences linked to socioeconomic factors relevant to Alzheimer's disease. If you work in Alzheimer's disease, or indeed other dementias, then Sex and Gender Differences in Alzheimer's disease is a must have for your bookshelf." -- Sabina Brennan, PhD., C.Psychol.,PsSI., National representative for Ireland on Alzheimer Disease International's Medical and Scientific Advisory Panel
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.
